Model-based evaluation environment for sustainability

Nowadays, many companies are using enterprise models within an enterprise planning system to develop their business strategy. In order to follow a holistic sustainability approach, environmental, economic and social aspects have to be integrated into these models on a strategic, tactical and operational level. This results in an increased model complexity and requires mechanisms to ensure consistency and efficient model management. Furthermore, the user is confronted with a variety of data and is not able to perform model validation and verification as well as using the enterprise model as a tool for operational support. This paper presents an approach of a model-based evaluation environment by extending enterprise models with sustainability artefacts, to empower the users within their decision-making towards a sustainable enterprise orientation. A framework for contextual enterprise modelling is applied to provide configurable individual model evaluation and application views

Model-based evaluation environment for sustainability

Nowadays, many companies are using enterprise models within an enterprise planning system to develop their business strategy. In order to follow a holistic sustainability approach, environmental, economic and social aspects have to be integrated into these models on a strategic, tactical and operational level. This results in an increased model complexity and requires mechanisms to ensure consistency and efficient model management. Furthermore, the user is confronted with a variety of data and is not able to perform model validation and verification as well as using the enterprise model as a tool for operational support. This paper presents an approach of a model-based evaluation environment by extending enterprise models with sustainability artefacts, to empower the users within their decision-making towards a sustainable enterprise orientation. A framework for contextual enterprise modelling is applied to provide configurable individual model evaluation and application views

Timely and individualized heart failure management: need for implementation into the new guidelines

Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators and cardiac resynchronization therapies, which improved patients' symptoms and prognosis. Over the last 10 years, new HF drugs have merged targeting various pathways, such as those that simultaneously suppress the renin–angiotensin–aldosterone system and the breakdown of endogenous natriuretic peptides (e.g., sacubitril/valsartan), and those that inhibit the If channel and, thus, reduce heart rate (e.g., ivabradine). Furthermore, the treatment of patient comorbidities (e.g., iron deficiency) has shown to improve functional capacity and to reduce hospitalization rates, when added to standard therapy. More recently, other potential treatment mechanisms have been explored, such as the sodium/glucose co-transporter inhibitors, the guanylate cyclase stimulators and the cardiac myosin activators. In this review, we summarize the novel developments in HFrEF pharmacological and device therapy and discuss their implementation strategies into practice to further improve outcomes